Spider Venom Peptide YC18 Kills Staph with No Resistance After 35 Passages | Research

The takeaway

Disulfide-stabilized spider venom peptide YC18 showed potent anti-S. aureus activity (MIC 6.25 μg/mL) with no resistance development after 35 serial passages, selective membrane targeting, and in vivo efficacy.

Zero resistance
Unlike vancomycin, S. aureus could not develop resistance to YC18 after 35 serial passages — a remarkable stability of antimicrobial potency

What the researchers found

YC18 showed MIC 6.25 μg/mL against S. aureus, no resistance after 35 passages, selective PG membrane targeting, dual-disulfide stability (Cys2-Cys15, Cys6-Cys11), high plasma stability, low cytotoxicity, and in vivo efficacy.

Why it matters

S. aureus infections including MRSA cause enormous morbidity. A peptide that bacteria can't become resistant to could be a game-changing antibiotic.

How the study worked

cDNA library screening from C. liboensis venom, MIC assays, 35-passage resistance development study, structural prediction and analog studies, MD simulations for membrane interaction, plasma stability, cytotoxicity, and murine infection models.

What this study cannot tell us

Tested primarily against S. aureus; broader spectrum needs assessment. In vivo testing limited. Manufacturing costs for disulfide-bonded peptides may be high.

How to read the evidence

Comprehensive preclinical study from discovery through in vivo validation with mechanistic characterization. Strong drug candidate profile.

When this study was published

Published in 2025.

The bigger picture

Spider venom continues to yield peptides with unique antimicrobial properties. YC18's resistance-proof mechanism and selective membrane targeting make it a standout drug candidate.

Questions still open

Is YC18 effective against MRSA and other drug-resistant staphylococcal strains?
Can the dual-disulfide scaffold be simplified for easier manufacturing?
Would YC18 work topically for wound infections?

Common questions

Why can't bacteria become resistant to this peptide?

YC18 targets phosphatidylglycerol, a fundamental component of bacterial membranes. Changing this would be like bacteria trying to rebuild their entire cell wall — it's so essential that resistance mutations would be lethal to the bacteria.

How does a spider venom peptide become medicine?

Researchers identified the peptide from venom, characterized its structure and mechanism, confirmed it's safe for human cells, and proved it works in mouse infections. Next steps would be optimization for human use and clinical trials.

Read the original research

Disulfide-bonded YC18: A membrane-targeting peptide with superior efficacy against Staphylococcus aureus infections.

Bioorganic chemistry, 168, 109322

View on PubMed ↗Publisher’s paper ↗

Citation

Gao, Jinai; Wang, Yi; Wang, Wanting; Yang, Min; Cao, Kaixun; Pan, Qi; Guo, Ruiyin; Lu, Qiumin; Zhang, Chengchen; Li, Juan; Lai, Ren. (2026). Disulfide-bonded YC18: A membrane-targeting peptide with superior efficacy against Staphylococcus aureus infections.. Bioorganic chemistry, 168, 109322. https://doi.org/10.1016/j.bioorg.2025.109322